[go: up one dir, main page]

UY34863A - Antagonistas de iap - Google Patents

Antagonistas de iap

Info

Publication number
UY34863A
UY34863A UY0001034863A UY34863A UY34863A UY 34863 A UY34863 A UY 34863A UY 0001034863 A UY0001034863 A UY 0001034863A UY 34863 A UY34863 A UY 34863A UY 34863 A UY34863 A UY 34863A
Authority
UY
Uruguay
Prior art keywords
iap antagonists
fórmula
pág
iap
antagonists
Prior art date
Application number
UY0001034863A
Other languages
English (en)
Inventor
Robert M Borzilleri
Heidi L Perez
Erik M Stang
Kim S Kyoung
Original Assignee
Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware filed Critical Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware
Publication of UY34863A publication Critical patent/UY34863A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describen compuestos que modulan la actividad de los inhibidores de la actividad de la apoptosis (IAP), composiciones farmacéuticas que contienen esos compuestos y métodos para tratar trastornos proliferativos y trastornos de apoptosis desregulada, tal como cáncer, mediante el uso de los compuestos de la invención.
UY0001034863A 2012-06-19 2013-06-18 Antagonistas de iap UY34863A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261661460P 2012-06-19 2012-06-19
US201361787808P 2013-03-15 2013-03-15

Publications (1)

Publication Number Publication Date
UY34863A true UY34863A (es) 2013-12-31

Family

ID=48699353

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001034863A UY34863A (es) 2012-06-19 2013-06-18 Antagonistas de iap

Country Status (6)

Country Link
US (1) US8889712B2 (es)
EP (1) EP2861581B9 (es)
AR (1) AR091490A1 (es)
TW (1) TW201402613A (es)
UY (1) UY34863A (es)
WO (1) WO2013192286A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014047024A1 (en) * 2012-09-18 2014-03-27 Bristol-Myers Squibb Company Iap antagonists
US9637518B2 (en) * 2013-07-12 2017-05-02 Bristol-Myers Squibb Company IAP antagonists
WO2016079527A1 (en) 2014-11-19 2016-05-26 Tetralogic Birinapant Uk Ltd Combination therapy
WO2016097773A1 (en) 2014-12-19 2016-06-23 Children's Cancer Institute Therapeutic iap antagonists for treating proliferative disorders
WO2017194390A1 (en) * 2016-05-09 2017-11-16 F. Hoffmann-La Roche Ag Dimeric compounds
EP3512833B1 (en) 2016-09-15 2020-07-29 Boehringer Ingelheim International GmbH Heteroaryl carboxamide compounds as inhibitors of ripk2
US20210371459A1 (en) * 2017-07-25 2021-12-02 Hepagene Therapeutics (HK) Limited Dimeric peptide inhibitors of apoptosis proteins
JP7536655B2 (ja) 2018-05-29 2024-08-20 オメロス コーポレーション Ｍａｓｐ－２阻害剤および使用方法
CA3107453A1 (en) * 2018-07-23 2020-01-30 Ohio State Innovation Foundation Derivatives of papaverine that are effective hypoxic tumor radiosensitizers
US11661418B2 (en) 2019-12-04 2023-05-30 Omeros Corporation MASP-2 inhibitors and methods of use
WO2021113698A1 (en) 2019-12-04 2021-06-10 Omeros Corporation Masp-2 inhibitors and methods of use
IL293550A (en) 2019-12-04 2022-08-01 Omeros Corp 2-masp inhibitor compounds, preparations containing them and their uses
BR112022010890A2 (pt) 2019-12-04 2022-08-16 Omeros Corp Composto, composição farmacêutica, e, método para tratar uma doença ou distúrbio associado a serina protease-2 associada à lectina de ligação ao manan

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5212157A (en) 1989-06-06 1993-05-18 Bio-Mega, Inc. Enzyme inhibitors
US20110117081A1 (en) * 2008-05-05 2011-05-19 Aegera Therapeutics, Inc. Functionalized pyrrolidines and use thereof as iap inhibitors
WO2013071027A1 (en) 2011-11-09 2013-05-16 Ensemble Therapeutics Macrocyclic compounds for inhibition of inhibitors of apoptosis
WO2013071035A1 (en) 2011-11-09 2013-05-16 Ensemble Therapeutics Macrocyclic compounds for inhibition of inhibitors of apoptosis
WO2013071039A1 (en) 2011-11-09 2013-05-16 Ensemble Therapeutics Macrocyclic compounds for inhibition of inhibitors of apoptosis

Also Published As

Publication number Publication date
US8889712B2 (en) 2014-11-18
EP2861581A1 (en) 2015-04-22
EP2861581B1 (en) 2017-02-01
EP2861581B9 (en) 2017-08-30
AR091490A1 (es) 2015-02-11
US20130338081A1 (en) 2013-12-19
WO2013192286A1 (en) 2013-12-27
TW201402613A (zh) 2014-01-16

Similar Documents

Publication Publication Date Title
UY34863A (es) Antagonistas de iap
UY34820A (es) Compuestos tipo pirrolo-pirrolidinona
UY34765A (es) Compuestos novedosos.
UY34778A (es) ?COMPUESTOS DE HEXAHIDROPIRANO[3,4-d][1,3]TIAZIN-2-AMINA HETEROCÍCLICOS SUSTITUÍDOS?.
UY34817A (es) Tienopirimidinas
UY34302A (es) COMPUESTOS DE HEXAHIDROPIRANO[3,4-d][1,3]TIAZIN-2- AMINA
UY34824A (es) Nucleósidos de espirooxetano de uracilo
UY34591A (es) Compuestos de imidazopirrolidinona
UY34763A (es) Inhibidores de la agregación plaquetaria
UY34515A (es) Triazolopiridinas sustituidas
UY34648A (es) Amidas como inhibidores de pim
UY34503A (es) ?sal de bromhidrato de pridopidina?
UY34550A (es) Bencilpirazoles sustituidos
UY34585A (es) Compuestos b-lactámicos sustituidos con amidina, su preparación y uso
UY34559A (es) Inhibidores de bromodominios
UY34586A (es) Nuevas 5,8-dihidro-6h-pirazolo[3,4-h]quinazolinas como inhibidores de igf-1r/ir
UY34767A (es) Inhibidores cíclicos del enlace éter de dgat1
UY34730A (es) Formulaciones farmacéuticas que comprenden antagonistas de ccr3
UY4223Q (es) Banco
UY34610A (es) Pirroldicarboxamidas condensadas y su uso como agentes farmacéuticos.
TR201905787T4 (tr) Liyofilize TAT-NR2B9C formülasyonu.
UY34629A (es) Inhibidores de pirazolopirimidinilo de enzima activadora de ubicuitina
UY34412A (es) ?pesticidas heterocíclicos sustituidos con 1,3-diarilo?.
UY34590A (es) Fenilimidazopirazoles sustituidos y su uso
UY34791A (es) N-etil-4-hidroxil-1-metil-5-(metil(2,3,4,5,6-pentahidroxihexil)amino)-2-oxo-n-fenil-1,2- dihidroquinolina-3-carboxamida